b'TRB MRD Clonality AssayBackgroundCombinations of chemotherapy, radiation therapy andnucleotides within the junctional region, generating bone marrow transplantation are potentially curativespecific and unique sequences within each lymphocyte. for several hematologic malignancies. However, in someCancer cells that arise from alterations in single lymphoid patients, occult tumor cells exist and are thought to increaseprecursors acquire clonal TRB junctional regions which can the patients risk of relapse. 1These subclinical levels ofbe used as tumor-specific markers. 2,3residual leukemia are termed minimal residual disease (MRD) and can be evaluated using sensitive assays. MRD detection by Next-Generation Sequencing has demonstrated utility in predicting clinical outcomes The tracking of antigen-receptor gene rearrangementsand in generating clinically actionable results, allowing for clonality analyses and MRD monitoring can be appliedearly intervention, confirmation of disease status prior to to virtually all patients. During early T-cell development,transplant, and increased confidence in remission status.the germline variable (V), diversity (D), and joining (J) fragments of the T-cell receptor beta (TRB) locus become rearranged through the random deletion or insertion of References1. Rezuke, W.N. et al. (1997) Molecular diagnosis of B- and T-cell lymphomas: fundamental principles and clinical applications. Clin Chem 43:1814-23.2.Gazzola, A. et al. (2014) The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies.Ther Adv Hematol. 5:35-47.3.Gonzlez, D. et al. (2007) Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110:3112-2144'